检索结果 - Patricia LoRusso

Refine Results
  1. 1
    Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

    Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors 由 Patricia LoRusso

    出版 2016
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Review: Targeting the Hedgehog pathway in cancer

    Review: Targeting the Hedgehog pathway in cancer 由 Sachin Gupta, Naoko Takebe, Patricia LoRusso

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Targeting the epidermal growth factor receptor

    Targeting the epidermal growth factor receptor 由 B. F. El-Rayes, Patricia LoRusso

    出版 2004
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be

    The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be 由 Ryan J. Sullivan, Patricia LoRusso, Keith T. Flaherty

    出版 2013
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  5. 5
    BET inhibitors: a novel epigenetic approach

    BET inhibitors: a novel epigenetic approach 由 Deborah Blythe Doroshow, J.P. Eder, Patricia LoRusso

    出版 2017
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  6. 6
    Clinical experience of MEK inhibitors in cancer therapy

    Clinical experience of MEK inhibitors in cancer therapy 由 Ding Wang, Scott A. Boerner, James D. Winkler, Patricia LoRusso

    出版 2006
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  7. 7
    Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients

    Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients 由 Xun Bao, Jianmei Wu, Seongho Kim, Patricia LoRusso, Jing Li

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Next-Generation Sequencing to Guide Clinical Trials

    Next-Generation Sequencing to Guide Clinical Trials 由 Lillian L. Siu, Barbara A. Conley, Scott A. Boerner, Patricia LoRusso

    出版 2015
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  9. 9
    A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer

    A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer 由 Elaina M. Gartner, Paula Silverman, Michael S. Simon, Lawrence E. Flaherty, Judith Abrams, Percy Ivy, Patricia LoRusso

    出版 2011
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors

    AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors 由 Elizabeth R. Plimack, Patricia LoRusso, Patricia McCoon, Weifeng Tang, Annetta Krebs, Gregory A. Curt, Sabine Eckhardt

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Clinical Pharmacokinetics and Exposure‐Toxicity Relationship of a Folate‐<i>Vinca</i> Alkaloid Conjugate EC145 in Cancer Patients

    Clinical Pharmacokinetics and Exposure‐Toxicity Relationship of a Folate‐<i>Vinca</i> Alkaloid Conjugate EC145 in Cancer Patients 由 Jing Li, Edward A. Sausville, Patrick Klein, David Morgenstern, Christopher P. Leamon, Richard A. Messmann, Patricia LoRusso

    出版 2009
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

    Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures 由 Vivek Subbiah, Aung Naing, Robert Brown, Helen Chen, L. Austin Doyle, Patricia LoRusso, Robert S. Benjamin, Pete Anderson, Razelle Kurzrock

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study

    Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study 由 Patricia LoRusso, Anthony F. Shields, Shirish M. Gadgeel, Ulka N. Vaishampayan, Tina Guthrie, Thomas A. Puchalski, John Xu, Qi Liu

    出版 2010
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer 由 Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

    Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors 由 Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel J. Robbie, Robert J. Lechleider

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

    Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma 由 Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, H. X. Chen, L. Austin Doyle, Alexandria T. Phan, Mouhammed Amir Habra, Razelle Kurzrock

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

    A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors 由 Renata Ferrarotto, Gail Eckhardt, Akash Patnaik, Patricia LoRusso, L. Faoro, John V. Heymach, Ann M. Kapoun, Lu Xu, P.N. Munster

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

    Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors 由 Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph A. Ludwig, Helen X. Chen, L. Austin Doyle, Razelle Kurzrock

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Differentiation and Definition of Vascular-Targeted Therapies

    Differentiation and Definition of Vascular-Targeted Therapies 由 Dietmar W. Siemann, Michael C. Bibby, G. Dark, Adam P. Dicker, Ferry A.L.M. Eskens, Michael R. Horsman, Dieter Marmé, Patricia LoRusso

    出版 2005
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series 由 Noboru Yamamoto, Anthony W. Tolcher, Navid Hafez, Iwona Ługowska, Rodryg Ramlau, Teresa Macarulla, Junxian Geng, Jian Li, Michael Teufel, Angela Märten, Patricia LoRusso

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: